Immunological and functional aspects of MAGEA3 cancer/testis antigen
- 1 January 2021
- book chapter
- Published by Elsevier
- Vol. 125, 121-147
Abstract
No abstract availableKeywords
Funding Information
- Department of Biotechnology, Ministry of Science and Technology, India (BT/PR13502/MED/30/1555/2015)
This publication has 157 references indexed in Scilit:
- IRF1 and NF-kB Restore MHC Class I-Restricted Tumor Antigen Processing and Presentation to Cytotoxic T Cells in Aggressive NeuroblastomaPLOS ONE, 2012
- What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?Annals of Oncology, 2012
- Immunotherapies for non-small-cell lung cancer and mesotheliomaThe Lancet Oncology, 2012
- Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinomaBritish Journal of Cancer, 2012
- TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune TargetsJournal of Immunology Research, 2012
- MAGE I Transcription Factors Regulate KAP1 and KRAB Domain Zinc Finger Transcription Factor Mediated Gene RepressionPLOS ONE, 2011
- MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of SurvivinClinical Cancer Research, 2011
- Inhibition of Histone Lysine Methylation Enhances Cancer–Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of CancerCancer Research, 2011
- Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell linesBMC Cancer, 2010
- MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agentsProceedings of the National Academy of Sciences, 2006